Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of CYD Dengue Vaccine in Healthy Children and Adolescents
NCT00993447Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2009
- Primary completion
- Sep 2011
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever, sponsored by Sanofi. Started Oct 2009; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT00993447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00993447.